Propanc Biopharma, Inc. (PPCB)
↓ Download CSVKey ratios (FY2025)
-423.7%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | — | — | $28.1K | $30.5K | $29.0K | — |
| Operating Income | -$57.28M | -$1.54M | -$1.78M | -$1.99M | -$1.81M | -$3.49M | -$2.61M | -$3.96M | -$5.74M | -$6.90M |
| Net Income | -$58.92M | -$1.82M | -$2.66M | -$2.66M | -$2.03M | -$4.74M | -$5.76M | -$7.04M | -$7.87M | -$9.41M |
| EPS (Diluted) | $-14.85 | $-1420.53 | $-1.80 | $-49.23 | $-0.80 | — | — | — | — | — |
| Total Assets | $19.63M | $72.4K | $60.3K | $81.7K | $13.1K | $98.5K | $101.7K | $71.4K | $95.1K | $379.1K |
| Total Liabilities | $5.73M | $3.85M | $3.18M | $3.11M | $3.08M | $3.74M | $4.40M | — | — | — |
| Shareholders' Equity | $13.91M | -$3.78M | -$3.12M | -$3.02M | -$3.07M | -$3.64M | -$4.30M | -$6.75M | -$5.44M | -$2.57M |
| Cash & Equivalents | — | — | — | $4.1K | $2.3K | $67.0K | — | — | — | — |
| Operating Cash Flow | -$405.2K | -$935.1K | -$1.11M | -$1.44M | -$1.15M | -$1.85M | -$2.06M | -$2.18M | -$2.05M | — |
| Capital Expenditures | — | — | — | — | — | — | $2.9K | — | — | $9.9K |
| Shares Outstanding | 11.61M | 8.0K | 6.03M | 220.4K | 14.06M | 258.1K | 968.0K | 92.8K | 4.55M | 2.91M |